Supplementary Data File S6 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Natalia Filippova,Xiuhua Yang,Subramaniam Ananthan,Jennifer Calano,Vibha Pathak,Larry Bratton,Rakesh H. Vekariya,Sixue Zhang,Edward Ofori,Emily N. Hayward,David Namkoong,David K. Crossman,Michael R. Crowley,Peter H. King,James A. Mobley,Louis B. Nabors

DOI: https://doi.org/10.1158/0008-5472.22429090.v1

2023-01-01

Abstract:File (tmp-LBN-Report_PH-DMPK-UAB-19-001_SRI-42127 _Mouse IP Plasma Brain PK) provides pharmacokinetic data for Fig. S14.

What problem does this paper attempt to address?

Supplementary Data File S2 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Natalia Filippova,Xiuhua Yang,Subramaniam Ananthan,Jennifer Calano,Vibha Pathak,Larry Bratton,Rakesh H. Vekariya,Sixue Zhang,Edward Ofori,Emily N. Hayward,David Namkoong,David K. Crossman,Michael R. Crowley,Peter H. King,James A. Mobley,Louis B. Nabors

DOI: https://doi.org/10.1158/0008-5472.22429105

2023-01-01

Abstract:File (tmp-LBN-Inhibitor vs DMSO DESeq2 annotated results with normalized counts) provides RNA-Seq annotated data for Fig. 6 and Table 1, which illustrate transcriptome analysis for PDGx neurospheres treated with SRI-42127 compound versus control.
Supplementary Data File S1 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Natalia Filippova,Xiuhua Yang,Subramaniam Ananthan,Jennifer Calano,Vibha Pathak,Larry Bratton,Rakesh H. Vekariya,Sixue Zhang,Edward Ofori,Emily N. Hayward,David Namkoong,David K. Crossman,Michael R. Crowley,Peter H. King,James A. Mobley,Louis B. Nabors

DOI: https://doi.org/10.1158/0008-5472.22429108.v1

2023-01-01

Abstract:File (DATA FILE S1 Lead optimization-SAR-Chemical compound synthesis-11-03-2020-SZ v4, pdf format 297 pages) provides a detailed and sequential description of the chemical synthesis of compounds evaluated in this study and a docking study for SRI-42127 compound with SRI-42127-binding sites at HuR.
Supplementary Data from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Natalia Filippova,Xiuhua Yang,Subramaniam Ananthan,Jennifer Calano,Vibha Pathak,Larry Bratton,Rakesh H. Vekariya,Sixue Zhang,Edward Ofori,Emily N. Hayward,David Namkoong,David K. Crossman,Michael R. Crowley,Peter H. King,James A. Mobley,Louis B. Nabors

DOI: https://doi.org/10.1158/0008-5472.22429084.v1

2023-01-01

Abstract:Supplementary materials including tables, figures, and detailed methods.
Supplementary Data File 4 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421117.v1

2023-01-01

Abstract:Pathway stability in PDXs across passages for Reactome pathway sets.
Supplementary Data File 3 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421120.v1

2023-01-01

Abstract:Pathway stability in PDXs across passages for Hallmark pathway set.
Supplementary Data File 6 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421111.v1

2023-01-01

Abstract:Association between drug class and pathways in PDXs. Drugs have been classified into categories according to their known target and association is computed using gene set enrichment analysis.
Supplementary Data File 5 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421114.v1

2023-01-01

Abstract:Analysis of drug response predicting biomarkers in PDXE dataset. For each tissue type and drug, association between genomic features (mutation copy number variation and gene expression) and drug response in PDXs are reported.
Additional File 9 of CircCDKN2B-AS1 Interacts with IMP3 to Stabilize Hexokinase 2 Mrna and Facilitate Cervical Squamous Cell Carcinoma Aerobic Glycolysis Progression

Yanan Zhang,Liang Zhao,Shizhou Yang,Yixuan Cen,Tingjia Zhu,Lingfang Wang,Lili Xia,Yuwan Liu,Jian Zou,Junfen Xu,Yang Li,Xiaodong Cheng,Weiguo Lü,Xinyu Wang,Xian-Jin Xie

DOI: https://doi.org/10.6084/m9.figshare.13466847

2020-01-01

Abstract:Additional file 9: Table S5. All proteins predicted by RBPmap.
Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Lauren A. Byers,Jing Wang,Monique B. Nilsson,Junya Fujimoto,Pierre Saintigny,John S. Yordy,Uma Giri,Michael Peyton,You Hong Fan,Lixia Diao,Fatemeh Masrorpour,Li Shen,Wenbin Liu,Boris Duchemann,Praveen K. Tumula,Vikas Bhardwaj,James Welsh,Stephanie Weber,Bonnie S. Glisson,Neda Kalhor,Ignacio I. Wistuba,Luc Girard,Scott M. Lippman,Gordon B. Mills,Kevin R. Coombes,John N. Weinstein,John D. Minna,John V. Heymach

DOI: https://doi.org/10.1158/2159-8290.22528410.v1

2023-01-01

Abstract:PDF file, 95K, Antibodies used in reverse-phase protein microarrays
Supplementary Data File 1 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421126.v1

2023-01-01

Abstract:Time vs. tumor volume plots for all 4,483 PDXs from PDXE dataset, generated using Xeva function plotPDX.
Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy

Xue-Bin Ran,Ling-Wen Ding,Qiao-Yang Sun,Henry Yang,Jonathan W. Said,Lao Zhentang,Vikas Madan,Pushkar Dakle,Jin-Fen Xiao,Xinyi Loh,Ying Li,Liang Xu,Xiao-Qiang Xiang,Ling-Zhi Wang,Boon Cher Goh,De-Chen Lin,Wee Joo Chng,Soo-Yong Tan,Sudhakar Jha,H. Phillip Koeffler

DOI: https://doi.org/10.1158/0008-5472.22432644.v1

2023-01-01

Abstract:<p>This file contains supplementary methods, Figs. S1 to S6 and Tables S1 to S5.</p>
Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Jeff Hsu,Colin Chong,Jeffrey Serrill,Levina Goon,Joan Balayan,Eric N. Johnson,Grachelle Lorenzana,Sharon Wu,Kevin G. Leong,Theodore J. Yun,Yong Wang,Faming Jiang,Lynne Bannen,Peter Lamb,Wei Xu,Peiwen Yu

DOI: https://doi.org/10.1158/1535-7163.22523460

2023-01-01

Abstract:Supplementary Figures and Tables with adjoining Legends
Supplementary File 1 from Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy

Junyu Yang,Chong Gao,Miao Liu,Yao-Chung Liu,Junsu Kwon,Jun Qi,Xi Tian,Alicia Stein,Yanjing V. Liu,Nikki R. Kong,Yue Wu,Shenyi Yin,Jianzhong Xi,Zhiyuan Chen,Kalpana Kumari,Hannan Wong,Hongbo Luo,Leslie E. Silberstein,Julie A.I. Thoms,Ashwin Unnikrishnan,John E. Pimanda,Daniel G. Tenen,Li Chai

DOI: https://doi.org/10.1158/0008-5472.22430467

2023-01-01

Abstract:List of primers used in the paper
Supplementary Data from Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response

Shilpak Chatterjee,Paramita Chakraborty,Anusara Daenthanasanmak,Supinya Iamsawat,Gabriela Andrejeva,Libia A. Luevano,Melissa Wolf,Uday Baliga,Carsten Krieg,Craig C. Beeson,Meenal Mehrotra,Elizabeth G. Hill,Jeffery C. Rathmell,Xue-Zhong Yu,Andrew S. Kraft,Shikhar Mehrotra

DOI: https://doi.org/10.1158/1078-0432.22469031

2023-01-01

Abstract:Supplementary Figures and Figure Legends
Supplementary Materials 2 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Humam Kadara,Li Shen,Junya Fujimoto,Pierre Saintigny,Chi-Wan Chow,Wenhua Liu,Zuoming Chu,Melinda Garcia,Mohamed Kabbout,You-Hong Fan,Carmen Behrens,Diane A. Liu,Mao Li,J. Jack Lee,Kathryn A. Gold,Jing Wang,Kevin R. Coombes,Edward S. Kim,Waun Ki Hong,Ignacio I. Wistuba

DOI: https://doi.org/10.1158/1940-6207.22524618.v1

2023-01-01

Abstract:PDF file - 6272K, Sweave report depicting complete codes used for microarray analysis and identification of genes differentially expressed by site and time
Supplementary Data DS1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Xuyang Song,Robin K. Kelley,Anis A. Khan,Nathan Standifer,Diansong Zhou,KyoungSoo Lim,Rajesh Krishna,Lu Liu,Kun Wang,Patricia McCoon,Alejandra Negro,Philip He,Megan Gibbs,John F. Kurland,Ghassan K. Abou‐Alfa

DOI: https://doi.org/10.1158/1078-0432.22490323.v1

2023-01-01

Abstract:Supplementary Data for publication
Supplemental Table S4 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Jing Zhang,Sun Min Lim,Mi Ra Yu,Cheng Chen,Jia Wang,Wenqian Wang,Haopeng Rui,Jingtao Lu,Shun Lu,Tony Mok,Zhi Jian Chen,Byoung Chul Cho

DOI: https://doi.org/10.1158/2159-8290.26934992

2024-01-01

Abstract:Supplemental Table S4 summarizing RNAseq and WES analysis of acquired resistant clones from MIA PaCa-2 xenograft model.
Fig S1-S8 from Aberrant FGFR Tyrosine Kinase Signaling Enhances the Warburg Effect by Reprogramming LDH Isoform Expression and Activity in Prostate Cancer

Junchen Liu,Guo Chen,Zezhen Liu,Shaoyou Liu,Zhiduan Cai,Pan You,Yuepeng Ke,Li Lai,Yun Huang,Hongchang Gao,Liangcai Zhao,Helene Pelicano,Peng Huang,Wallace L. McKeehan,Chin-Lee Wu,Cong Wang,Weide Zhong,Fen Wang

DOI: https://doi.org/10.1158/0008-5472.22419839.v1

2023-01-01

Abstract:This file containing all the supplemental data supporting the statements indicated in the manuscripts.
Supplemental Figure S7 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Jing Zhang,Sun Min Lim,Mi Ra Yu,Cheng Chen,Jia Wang,Wenqian Wang,Haopeng Rui,Jingtao Lu,Shun Lu,Tony Mok,Zhi Jian Chen,Byoung Chul Cho

DOI: https://doi.org/10.1158/2159-8290.26935010.v1

2024-01-01

Abstract:Supplemental Figure S7 shows data from translational exploration of CR6927 PDX model.
Supplementary Data from an <i>in Vivo</i> CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML

Shuo Lin,Clément Larrue,Nastassja K. Scheidegger,Bo Kyung A. Seong,Neekesh V. Dharia,Miljan Kuljanin,Caroline S. Wechsler,Guillaume Kugener,Amanda L. Robichaud,Amy Saur Conway,Thelma Mashaka,Sarah Mouche,Biniam Adane,Jeremy Ryan,Joseph D. Mancias,Scott T. Younger,Federica Piccioni,Lynn Lee,Mark Wunderlich,Anthony Letaï,Jérôme Tamburini,Kimberly Stegmaier

DOI: https://doi.org/10.1158/2159-8290.22540234.v1

2023-01-01

Abstract:Supplementary Data from An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML

Supplementary Data File S6 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Data File S2 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Data File S1 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Data from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Data File 4 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 3 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 6 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 5 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Additional File 9 of CircCDKN2B-AS1 Interacts with IMP3 to Stabilize Hexokinase 2 Mrna and Facilitate Cervical Squamous Cell Carcinoma Aerobic Glycolysis Progression

Supplementary Table 7 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Data File 1 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary file from Targeting RNA Exonuclease XRN1 Potentiates Efficacy of Cancer Immunotherapy

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary File 1 from Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy

Supplementary Data from Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response

Supplementary Materials 2 from Characterizing the Molecular Spatial and Temporal Field of Injury in Early-Stage Smoker Non–Small Cell Lung Cancer Patients after Definitive Surgery by Expression Profiling

Supplementary Data DS1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Supplemental Table S4 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Fig S1-S8 from Aberrant FGFR Tyrosine Kinase Signaling Enhances the Warburg Effect by Reprogramming LDH Isoform Expression and Activity in Prostate Cancer

Supplemental Figure S7 from D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities

Supplementary Data from an &lt;i&gt;in Vivo&lt;/i&gt; CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML

Supplementary Data from an <i>in Vivo</i> CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML